Tag: Drug patents

More than 38 million people in the U.S. have diabetes, with many relying on medications like empagliflozin [1.2.3]. So, is there a generic version of empagliflozin? While the FDA has approved generic versions, they are not yet available in the U.S. as of September 2025 [1.2.1, 1.2.2].

Despite the prevalence of generic medicines, the brand-name biologic Taltz (ixekizumab) currently has no generic version or biosimilar available. This is because Taltz is a complex biologic drug, not a simple chemical compound, which affects its generic and biosimilar development pathway.

As of 2025, there is no FDA-approved generic semaglutide available in the United States, a crucial fact for patients navigating expensive brand-name versions like Ozempic and Wegovy. This reality directly impacts whether your insurance will cover 'generic semaglutide'—the short answer being almost certainly no, as most plans do not cover non-FDA approved versions.

According to a 2023 study by ClinCalc, the average out-of-pocket cost per generic duloxetine prescription fill in the U.S. was approximately $11.97, a significant decrease from over $30 a decade prior. However, many patients still struggle to understand why is duloxetine so expensive, especially when comparing the brand-name product, Cymbalta, to its generic alternative. The price is influenced by a complex interplay of patents, generic competition, and the U.S. healthcare system's unique pricing dynamics.

As of 2025, there is no FDA-approved generic version of Ozempic (semaglutide) available in the United States, with patent protections potentially delaying a generic launch until at least 2031. This exclusivity means patients seeking a more affordable option face a complex landscape, including the risks associated with compounded alternatives.

As of late 2025, there is no therapeutically equivalent generic cabotegravir available for commercial use in the United States, although efforts via the Medicines Patent Pool aim to provide access in low- and middle-income countries. This article addresses the question, is there a generic for cabotegravir, and details the current situation regarding brand-name formulations and global access initiatives.

Approved by the FDA in 2023, Veozah (fezolinetant) is a non-hormonal treatment for hot flashes associated with menopause. A common question for many patients is, **is there a generic version of Veozah?** The short answer is no, and the reasons lie in the drug's recent approval and current patent protection.